De-intensification of treatment for human papilloma virus associated oropharyngeal squamous cell carcinoma: A discussion of current approaches

Practical Radiation Oncology

Volumn 2, Issue 4, 2012, Pages 282-287

  Patel, Sagar C ^a   Hackman, Trevor ^a,b   Hayes, David Neil ^a,b   Chera, Bhishamjit S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL; PROTEIN P16;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CASE REPORT; CHEMORADIOTHERAPY; DRUG MEGADOSE; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; NONHUMAN; ORAL SURGERY; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE; RADIATION SICKNESS; TONSIL CARCINOMA; TRANSORAL LASER MICROSURGERY; TRANSORAL ROBOTIC SURGERY; UNSPECIFIED SIDE EFFECT; WART VIRUS;

EID: 84866503500     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2011.10.002     Document Type: Article

References (36)

1. Chaturvedi A.K., Engels E.A., Anderson W.F., Gillison M.L. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008, 26:612-619.
2. Mork J., Lie A.K., Glattre E., et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001, 344:1125-1131.
3. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35.
4. Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100:261-269.
5. Licitra L., Perrone F., Bossi P., et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006, 24:5630-5636.
6. Lassen P., Eriksen J.G., Hamilton-Dutoit S., Tramm T., Alsner J., Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009, 27:1992-1998.
7. Smeets S.J., Braakhuis B.J., Abbas S., et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006, 25:2558-2564.
8. Westra W.H., Taube J.M., Poeta M.L., Begum S., Sidransky D., Koch W.M. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 2008, 14:366-369.
9. Kumar B., Cordell K.G., Lee J.S., et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008, 26:3128-3137.
10. Klussmann J.P., Mooren J.J., Lehnen M., et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res 2009, 15:1779-1786.
11. Braakhuis B.J., Snijders P.J., Keune W.J., et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004, 96:998-1006.
12. Weinberger P.M., Yu Z., Haffty B.G., et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006, 24:736-747.
13. Parsons J.T., Mendenhall W.M., Stringer S.P., et al. Squamous cell carcinoma of the oropharynx: Surgery, radiation therapy, or both. Cancer 2002, 94:2967-2980.
14. Weinstein G.S., Quon H., O'Malley B.W., Kim G.G., Cohen M.A. Selective neck dissection and deintensified postoperative radiation and chemotherapy for oropharyngeal cancer: A subset analysis of the University of Pennsylvania transoral robotic surgery trial. Laryngoscope 2010, 120:1749-1755.
15. Haughey BH, Hinni ML, Salassa JR, et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: A United States multicenter study [published online ahead of print January 31, 2011]. Head Neck. doi:10.1002/hed.21669.
16. Rich J.T., Milov S., Lewis J.S., Thorstad W.L., Adkins D.R., Haughey B.H. Transoral laser microsurgery (TLM) +/- adjuvant therapy for advanced stage oropharyngeal cancer: Outcomes and prognostic factors. Laryngoscope 2009, 119:1709-1719.
17. Grant D.G., Hinni M.L., Salassa J.R., Perry W.C., Hayden R.E., Casler J.D. Oropharyngeal cancer: A case for single modality treatment with transoral laser microsurgery. Arch Otolaryngol Head Neck Surg 2009, 135:1225-1230.
18. Grant D.G., Salassa J.R., Hinni M.L., Pearson B.W., Perry W.C. Carcinoma of the tongue base treated by transoral laser microsurgery, part one: Untreated tumors, a prospective analysis of oncologic and functional outcomes. Laryngoscope 2006, 116:2150-2155.
19. Weinstein G.S., O'Malley B.W., Cohen M.A., Quon H. Transoral robotic surgery for advanced oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2010, 136:1079-1085.
20. Cohen M.A., Weinstein G.S., O'Malley B.W., Feldman M., Quon H. Transoral robotic surgery and human papillomavirus status: Oncologic results. Head Neck 2011, 33:573-580.
21. Dirix P., Abbeel S., Vanstraelen B., Hermans R., Nuyts S. Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: Dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2009, 75:385-392.
22. Eisbruch A., Schwartz M., Rasch C., et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: Which anatomic structures are affected and can they be spared by IMRT?. Int J Radiat Oncol Biol Phys 2004, 60:1425-1439.
23. Feng F.Y., Kim H.M., Lyden T.H., et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: Early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2007, 68:1289-1298.
24. Jensen K., Lambertsen K., Grau C. Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: Frequency, intensity and correlation with dose and volume parameters. Radiother Oncol 2007, 85:74-82.
25. Levendag P.C., Teguh D.N., Voet P., et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: A dose-effect relationship. Radiother Oncol 2007, 85:64-73.
26. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004, 350:1945-1952.
27. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004, 350:1937-1944.
28. Bernier J., Cooper J.S., Pajak T.F., et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005, 27:843-850.
29. National Institutes of Health Paclitaxel, cisplatin, and cetuximab followed by cetuximab and intensity-modulated radiation therapy in treating patients with HPV-associated stage III or stage IV cancer of the oropharynx that can be removed by surgery Available at:, Updated August 24, 2011. Accessed August 24, 2011. http://www.clinicaltrial.gov/ct2/show/NCT01084083?term=01084083&rank=1.
30. National Institutes of Health Docetaxel/cisplatin/5-fluorouracil (tpf) human papillomavirus (hpv) squamous cell carcinoma study Available at:, Updated August 24, 2011. Accessed August 24, 2011. http://www.clinicaltrial.gov/ct2/show/NCT01221753?term=01221753&rank=1.
31. Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer Radiation Therapy Oncology Group, Available at:, Updated July 5, 2011. Accessed August 24, 2011. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1016.
32. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
33. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11:21-28.
34. Garden A.S., Asper J.A., Morrison W.H., et al. Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?. Cancer 2004, 100:1171-1178.
35. O'Sullivan B., Huang S., Perez-Ordonez B., et al. Outcome of radiotherapy alone in HPV associated oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2010, 78:S62-S63.
36. Pignon J.P., le Maître A., Maillard E., Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14. MACH-NC Collaborative Group.